Accordingly, Nrf2 activation in tumor cells enhances their malignancy, but Nrf2 activation in TME of the tumor cells triggers anticancer immunity, thus suppressing tumors (Figure 3) [168]. Here, NFE2L2 is linked to neoplasm.